Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 10;57(8):1250–1259. doi: 10.1038/s41409-022-01698-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a, b FasL treatment enhances HSPCs stemness demonstrating higher F510/F580 fluorescence ratio (FR) correlated with Glutathione (GSH) level. (a) Representative flow cytometry histogram (b) results of 3 independent experiments of MPBCs treatment with 100 ng/ml of FasL; Mean ± SEM *P ≤ 0.05; Paired T-test. c–i 7 Days expansion capacity after short (5 min, 1 h and 4 h) exposure of purified CD34⁺ cells with 100 ng/ml FasL. (c) Percentage of CD34⁺ cells per total cell population, (d) total cell number per well, (e–i) percentage of HSPCs subpopulations per total CD34⁺ population: (e) Self-renewal HSCs (CD34⁺CD38^neg/lowCD90⁺CD45RA⁻), (f) MPP (CD34⁺CD38^neg/low CD90⁻CD45RA⁻), (g) LMPP (CD38^Neg/LowCD90⁻CD45RA+), (h) OPP (CD38^+high), (i) early-stage MkPs (CD38^Neg/lowCD41a⁺), (c–h): N = 3, (i) N = 2, Mean ± SEM, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 Paired T-test.